Viva Biotech Holdings will hold its annual general meeting on 26 June 2026 at 10:00 a.m. (Meeting Room A615, 735 Ziping Road, Zhoupu Town, Pudong New District, Shanghai).

Key resolutions to be put to shareholders are summarised below:

1. 2025 financial statements • Shareholders will be asked to receive and adopt the audited consolidated results for the year ended 31 December 2025, together with the directors’ and auditor’s reports.

2. Board composition • Re-election of Mr Ren Delin (executive director), Mr Wu Yuting (non-executive director) and Mr Fu Lei (independent non-executive director). • Authorisation for the board to determine all directors’ remuneration.

3. Auditor • Re-appointment of Ernst & Young as external auditor, with fees to be set by the board.

4. General mandates • Issuance mandate: authority for the board to allot and issue new shares or convertible securities up to 20 % of Viva Biotech’s issued share capital, beyond specific exclusions such as rights issues and employee share schemes. • Repurchase mandate: authority to buy back shares on the Hong Kong Stock Exchange or other recognised markets, capped at 10 % of issued share capital. • Extension mandate: the share-issue limit may be increased by the nominal amount of any shares repurchased under the above buy-back authority, providing a potential additional 10 % capacity.

5. Administrative details • The Hong Kong share register will be closed from 23 June 2026 to 26 June 2026 (both days inclusive). Share transfers must be lodged by 4:30 p.m. on 22 June 2026 to qualify for attendance and voting. • Proxy forms must be deposited with Tricor Investor Services by 10:00 a.m. on 24 June 2026.

The board stated it has no immediate plans to issue new shares and will exercise the repurchase mandate only when deemed beneficial to shareholders.